Do Analysts Agree Tuesday on Kaleido Biosciences Inc (KLDO) Stock's Target Price?

Tuesday, April 12, 2022 01:20 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Agree Tuesday on Kaleido Biosciences Inc (KLDO) Stock's Target Price?

Wall Street is neutral on Kaleido Biosciences Inc (KLDO). On average, analysts give Kaleido Biosciences Inc a Buy rating. The average price target is $7.675, which means analysts expect the stock to rise by 5016.67% over the next twelve months. That average ranking earns Kaleido Biosciences Inc an Analyst Rating of 11, which is better than 11% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating KLDO a Buy today. Find out what this means to you and get the rest of the rankings on KLDO!

See Full KLDO Report

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers. InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Kaleido Biosciences Inc Stock Today?

Kaleido Biosciences Inc (KLDO) stock is lower by -23.8% while the S&P 500 is higher by 0.54% as of 1:19 PM on Tuesday, Apr 12. KLDO is lower by -$0.05 from the previous closing price of $0.20 on volume of 6,947,683 shares. Over the past year the S&P 500 is higher by 7.47% while KLDO is lower by -97.85%. KLDO lost -$2.16 per share the over the last 12 months. Click Here to get the full Stock Report for Kaleido Biosciences Inc stock.